Jasper Therapeutics
JSPR
41 hedge funds and large institutions have $91.4M invested in Jasper Therapeutics in 2023 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 11 increasing their positions, 9 reducing their positions, and 8 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
43% more capital invested
Capital invested by funds: $63.7M → $91.4M (+$27.7M)
22% more repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 9
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
3% more funds holding
Funds holding: 40 → 41 (+1)
1.34% less ownership
Funds ownership: 8.26% → 6.92% (-1.3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.67M |
| 2 |
Morgan Stanley
New York
|
+$1.76M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$1.05M |
| 4 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$530K |
| 5 |
ABG
Ally Bridge Group
New York
|
+$346K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$6.93M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.34M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$3.15M |
| 4 |
ACM
Altium Capital Management
New York
|
-$2.01M |
| 5 |
WP
Woodline Partners
San Francisco,
California
|
-$850K |
JSPR Hedge Fund Activity: Q4 2023 in Review
41 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q4 2023, worth a combined $91.4M — up 43% from $63.7M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new JSPR positions and 8 closed out — a net gain of 1 holder — while 11 added to existing stakes and 9 trimmed.
The largest buyer was Opaleye Management, opening a new position worth an estimated $2.67M. The largest seller was BVF Inc, exiting entirely with an estimated $6.93M sold.
- 41 institutional investors held Jasper Therapeutics (JSPR) as of Q4 2023, up from 40 in Q3 2023.
- Funds reported $91.4M of Jasper Therapeutics stock for Q4 2023, up 43% quarter-over-quarter.
- 9 funds opened new Jasper Therapeutics positions in Q4 2023 and 8 closed out, a net change of +1 holder.
- The largest Jasper Therapeutics buyer in Q4 2023 was Opaleye Management, an estimated $2.67M added.
- The largest Jasper Therapeutics seller in Q4 2023 was BVF Inc, an estimated $6.93M sold.
Based on aggregated 13F filings for Q4 2023.